Mesoblast Limited (MEOBF)
USD 1.03
(0.0%)
USD 1.03
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -62.38 Million USD | -3.38% |
| 2023 | -60.77 Million USD | 15.08% |
| 2022 | -66.52 Million USD | 28.84% |
| 2021 | -79.93 Million USD | -42.7% |
| 2020 | -70.83 Million USD | 7.09% |
| 2019 | -83.31 Million USD | -8.67% |
| 2018 | -60.36 Million USD | 16.97% |
| 2017 | -86.98 Million USD | -220.42% |
| 2016 | -94.61 Million USD | 75.77% |
| 2015 | -90.19 Million USD | -72.91% |
| 2014 | -66.23 Million USD | -12.99% |
| 2013 | -59.7 Million USD | -125.25% |
| 2012 | -49.55 Million USD | -128.48% |
| 2011 | 92.43 Million USD | 942.36% |
| 2010 | -10.97 Million USD | -17.88% |
| 2009 | -9.3 Million USD | -19.61% |
| 2008 | -7.78 Million USD | 10.18% |
| 2007 | -6.95 Million USD | -6.39% |
| 2006 | -8.14 Million USD | -505.9% |
| 2005 | -1.34 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -15.25 Million USD | -19.39% |
| 2024 Q4 | -15.25 Million USD | 0.0% |
| 2024 FY | - USD | 20.83% |
| 2024 Q1 | -12.78 Million USD | 26.79% |
| 2024 Q2 | -12.78 Million USD | 0.0% |
| 2023 Q3 | -13.47 Million USD | 32.73% |
| 2023 Q1 | -14.9 Million USD | 20.17% |
| 2023 Q4 | -16.98 Million USD | -26.04% |
| 2023 FY | - USD | 15.08% |
| 2023 Q2 | -20.02 Million USD | -34.42% |
| 2022 Q3 | -18.22 Million USD | 22.56% |
| 2022 Q4 | -18.66 Million USD | -2.41% |
| 2022 FY | - USD | 28.84% |
| 2022 Q1 | -19.32 Million USD | -6.39% |
| 2022 Q2 | -23.53 Million USD | -21.78% |
| 2021 Q2 | -26.31 Million USD | 29.94% |
| 2021 Q1 | -37.56 Million USD | -21.23% |
| 2021 Q4 | -18.16 Million USD | 26.82% |
| 2021 FY | - USD | -42.7% |
| 2021 Q3 | -24.82 Million USD | 5.67% |
| 2020 Q4 | -30.98 Million USD | -112.59% |
| 2020 FY | - USD | 7.09% |
| 2020 Q3 | -14.57 Million USD | 36.22% |
| 2020 Q2 | -22.85 Million USD | -648.2% |
| 2020 Q1 | -3.05 Million USD | 82.62% |
| 2019 Q3 | -21.68 Million USD | 8.34% |
| 2019 Q2 | -23.65 Million USD | -45.75% |
| 2019 Q1 | -16.22 Million USD | 29.77% |
| 2019 FY | - USD | -8.67% |
| 2019 Q4 | -17.56 Million USD | 18.97% |
| 2018 Q1 | -28.42 Million USD | -84.1% |
| 2018 FY | - USD | 16.97% |
| 2018 Q3 | -23.6 Million USD | -203.51% |
| 2018 Q2 | -7.77 Million USD | 72.64% |
| 2018 Q4 | -23.11 Million USD | 2.11% |
| 2017 Q3 | -21.22 Million USD | 3.86% |
| 2017 Q4 | -15.44 Million USD | 27.25% |
| 2017 FY | - USD | -220.42% |
| 2017 Q2 | -22.07 Million USD | -4.61% |
| 2017 Q1 | -21.1 Million USD | -166.78% |
| 2016 Q2 | -20.39 Million USD | -48.1% |
| 2016 Q3 | -21.51 Million USD | -5.49% |
| 2016 FY | - USD | 75.77% |
| 2016 Q1 | -13.76 Million USD | 72.91% |
| 2016 Q4 | 31.6 Million USD | 246.93% |
| 2015 Q3 | -20.08 Million USD | 21.96% |
| 2015 Q4 | -50.83 Million USD | -153.09% |
| 2015 Q2 | -25.73 Million USD | -59.19% |
| 2015 Q1 | -16.16 Million USD | 11.7% |
| 2015 FY | - USD | -72.91% |
| 2014 Q2 | -18.28 Million USD | -78.54% |
| 2014 Q4 | -18.3 Million USD | 1.35% |
| 2014 FY | - USD | -12.99% |
| 2014 Q1 | -10.24 Million USD | 27.75% |
| 2014 Q3 | -18.55 Million USD | -1.49% |
| 2013 Q4 | -14.17 Million USD | 12.05% |
| 2013 FY | - USD | -125.25% |
| 2013 Q3 | -16.11 Million USD | 0.0% |
| 2012 FY | - USD | -128.48% |
| 2011 FY | - USD | 942.36% |
| 2010 FY | - USD | -17.88% |
| 2009 FY | - USD | -19.61% |
| 2008 FY | - USD | 10.18% |
| 2007 FY | - USD | -6.39% |
| 2006 FY | - USD | -505.9% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 12.172% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -952.297% |
| SQZ Biotechnologies Company | -64.14 Million USD | 2.73% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -259.181% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 166.345% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -3961.703% |
| Genus plc | 73.7 Million USD | 184.654% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -843.652% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -1658.945% |
| Marizyme, Inc. | -34.28 Million USD | -81.993% |
| ContraFect Corporation | -64.99 Million USD | 4.014% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -611.237% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -1278.415% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -4350.663% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -2259.273% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -2584.792% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -11943.283% |
| Accustem Sciences Inc. | -3.74 Million USD | -1565.317% |
| RVL Pharmaceuticals plc | -48.22 Million USD | -29.367% |
| EV Biologics, Inc. | -1.26 Million USD | -4823.697% |
| Q BioMed Inc. | -617.62 Thousand USD | -10001.508% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 1846.633% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -9765.457% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -2631.015% |
| Biomind Labs Inc. | -1.03 Million USD | -5930.622% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 731.667% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -771.21% |
| Skye Bioscience, Inc. | -13.54 Million USD | -360.524% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -4094.517% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -249458.976% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -1506.195% |
| IMV Inc. | -35.52 Million USD | -75.63% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -293.137% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -2393.633% |
| GB Sciences, Inc. | -1.41 Million USD | -4294.0% |
| Alpha Cognition Inc. | -9.7 Million USD | -542.822% |
| HST Global, Inc. | -5303.00 USD | -1176399.038% |
| CSL Limited | 4.78 Billion USD | 101.303% |
| Halberd Corporation | -74.27 Thousand USD | -83893.786% |
| Enzolytics Inc. | -2.12 Million USD | -2840.099% |
| Resverlogix Corp. | -11.74 Million USD | -431.338% |
| Affymax, Inc. | -14.29 Million USD | -336.445% |
| SYBLEU INC | -141.57 Thousand USD | -43969.579% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -1936.873% |
| argenx SE | -216.02 Million USD | 71.119% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | -12.741% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 5226.52% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -4062.352% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 16568.452% |
| AVAX Technologies, Inc. | -6.11 Million USD | -920.667% |
| Zenith Capital Corp. | -8.6 Million USD | -624.956% |
| Genscript Biotech Corporation | -248.71 Million USD | 74.916% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -358029.522% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -2450.204% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -35343.812% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | -57.403% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -2057.079% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -5862.824% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 927966.508% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -3465.13% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -3147.925% |
| BioStem Technologies, Inc. | -7.55 Million USD | -725.955% |
| ONE Bio Corp. | 13.61 Million USD | 558.309% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -34352.721% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -2933.045% |
| Agentix Corp. | -1.37 Million USD | -4448.166% |
| LadRx Corporation | 412.28 Thousand USD | 15232.747% |
| Cell Source, Inc. | -4.27 Million USD | -1360.254% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -16889.699% |
| Regen BioPharma, Inc. | 1.46 Million USD | 4355.908% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -6558.82% |
| NovAccess Global Inc. | -1.03 Million USD | -5929.177% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 804.666% |
| Itoco Inc. | -1.86 Million USD | -3238.144% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -16334.788% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -5490.479% |
| Kadimastem Ltd | -2.62 Million USD | -2277.313% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -25988.122% |
| CytoDyn Inc. | -18.02 Million USD | -246.052% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -78845.38% |
| Mobile Lads Corp. | -2.24 Million USD | -2683.816% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -510078.625% |
| Qrons Inc. | -40.08 Thousand USD | -155559.15% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -12745.907% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 11928.942% |
| Rebus Holdings, Inc. | -951 Thousand USD | -6460.436% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -5774.685% |
| International Stem Cell Corporation | 202 Thousand USD | 30986.012% |
| Bioxytran, Inc. | -3.82 Million USD | -1533.177% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -118421.55% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -2434.178% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | -73.938% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -138543.876% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -2178.661% |
| Neutra Corp. | -181.24 Thousand USD | -34322.497% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -209.488% |
| PureTech Health plc | -11.62 Million USD | -436.594% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | -209.51% |
| IXICO plc | -707 Thousand USD | -8724.575% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -711.838% |
| Gelesis Holdings, Inc. | -48.34 Million USD | -29.048% |
| CSL Limited | 4.73 Billion USD | 101.318% |
| Cellectis S.A. | -92.63 Million USD | 32.651% |